Compare Heron Therapeutics Inc (HRTX) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs T-Mobile Us Inc — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while T-Mobile Us Inc trades at $192.11 (market cap $211.72B). The key difference: T-Mobile Us Inc is far larger — about 2314.9× Heron Therapeutics Inc's market cap, and T-Mobile Us Inc pays a 2.09% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | TMUS | |
|---|---|---|
Market Cap | $91.46M | $211.72B |
Sector | Health | Media |
52-Week High | $1.96 | $259.01 |
52-Week Low | $0.39 | $167.65 |
Enterprise Value | $189.36M | $329.42B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
T-Mobile US (TMUS) trades at $195.37, up 1.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $88.3B revenue in 2025, 11.65% net margin, and consistent earnings beats in three of the last four quarters. Recent leadership changes and strategic appointments position TMUS for growth amid competitive pressures from satellite internet providers.
TMUS presents a compelling investment case with 83% analyst buy ratings and $238.40 consensus target, offering 22% upside. However, rising debt levels (39.35% debt-to-asset ratio) and Starlink competition pose significant risks. The stock's current RSI levels suggest potential near-term consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
